SLC5A2 and hydrops fetalis: Emerging therapies in HF demonstrate clear phenotype-specific benefits, with SGLT2 inhibitors effectively improving outcomes across both HFpEF and HFrEF and sGC stimulators like vericiguat significantly benefiting worsening HFrEF patients.